Stock Analysis Report

Executive Summary

SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally.

Snowflake Analysis

Flawless balance sheet and good value.

Similar Companies

Share Price & News

How has SHL Telemedicine's share price performed over time and what events caused price changes?

Latest Share Price and Events

Stable Share Price: SHLTN's share price has been volatile over the past 3 months.

Market Performance

7 Day Return




CH Healthcare


CH Market

1 Year Return




CH Healthcare


CH Market

Return vs Industry: SHLTN exceeded the Swiss Healthcare industry which returned -20.2% over the past year.

Return vs Market: SHLTN underperformed the Swiss Market which returned -5.4% over the past year.

Shareholder returns

7 Day11.3%4.1%2.2%
30 Day-6.8%-10.5%-2.9%
90 Day-1.8%-16.4%-11.3%
1 Year0.9%-14.7%-15.3%-16.7%1.4%-1.8%
3 Year-12.0%-25.7%-26.7%-29.6%17.5%6.0%
5 Year-21.1%-33.3%-11.7%-17.0%19.0%-0.5%

Price Volatility Vs. Market

How volatile is SHL Telemedicine's share price compared to the market and industry in the last 5 years?

Simply Wall St News


Is SHL Telemedicine undervalued compared to its fair value and its price relative to the market?


Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: SHLTN (CHF5.5) is trading below our estimate of fair value (CHF56.62)

Significantly Below Fair Value: SHLTN is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: SHLTN is good value based on its PE Ratio (11x) compared to the Healthcare industry average (19.1x).

PE vs Market: SHLTN is good value based on its PE Ratio (11x) compared to the Swiss market (16.2x).

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SHLTN's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: SHLTN is overvalued based on its PB Ratio (1.8x) compared to the XE Healthcare industry average (1.6x).

Next Steps

Future Growth

How is SHL Telemedicine forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?


Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as SHL Telemedicine has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Next Steps

Past Performance

How has SHL Telemedicine performed over the past 5 years?


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: SHLTN has high quality earnings.

Growing Profit Margin: SHLTN's current net profit margins (12.9%) are lower than last year (18.8%).

Past Earnings Growth Analysis

Earnings Trend: SHLTN has become profitable over the past 5 years, growing earnings by 30.8% per year.

Accelerating Growth: SHLTN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: SHLTN had negative earnings growth (-40.9%) over the past year, making it difficult to compare to the Healthcare industry average (-3.2%).

Return on Equity

High ROE: SHLTN's Return on Equity (16.5%) is considered low.

Next Steps

Financial Health

How is SHL Telemedicine's financial position?

Financial Position Analysis

Short Term Liabilities: SHLTN's short term assets ($17.6M) exceed its short term liabilities ($16.3M).

Long Term Liabilities: SHLTN's short term assets ($17.6M) exceed its long term liabilities ($4.3M).

Debt to Equity History and Analysis

Debt Level: SHLTN's debt to equity ratio (4.5%) is considered satisfactory.

Reducing Debt: SHLTN's debt to equity ratio has reduced from 39.4% to 4.5% over the past 5 years.

Debt Coverage: SHLTN's debt is well covered by operating cash flow (1219.8%).

Interest Coverage: SHLTN earns more interest than it pays, so coverage of interest payments is not a concern.

Balance Sheet

Next Steps


What is SHL Telemedicine's current dividend yield, its reliability and sustainability?


Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: SHLTN's dividend (17.76%) is higher than the bottom 25% of dividend payers in the Swiss market (2.05%).

High Dividend: SHLTN's dividend (17.76%) is in the top 25% of dividend payers in the Swiss market (4.46%)

Stability and Growth of Payments

Stable Dividend: SHLTN has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: SHLTN's dividend payments have increased, but the company has only paid a dividend for 9 years.

Current Payout to Shareholders

Dividend Coverage: With its high payout ratio (194.6%), SHLTN's dividend payments are not well covered by earnings.

Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.

Next Steps


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Yoav Rubinstein (46yo)





Mr. Yoav Rubinstein has been the Chief Executive Officer at SHL Telemedicine Ltd. since June 1, 2017. Mr. Rubinstein served as an Investment Manager of Apax Israel Investment Fund. He focused on buyouts an ...

CEO Compensation Analysis

Compensation vs Market: Yoav's total compensation ($USD1.04M) is above average for companies of similar size in the Swiss market ($USD697.22K).

Compensation vs Earnings: Insufficient data to compare Yoav's compensation with company performance.

Leadership Team

Yoav Rubinstein
Chief Executive Officer3yrsUS$1.04mno data
Yossi Vadnagra
Chief Financial Officer3yrsno datano data
Yoni Dagan
Chief Technology Officer3.17yrsno datano data
Ralf Bork
Managing Director of SHL Telemedizin0.92yrno datano data


Average Tenure

Experienced Management: SHLTN's management team is considered experienced (3 years average tenure).

Board Members

Erez Nachtomy
Director1.33yrsUS$2.54kno data
Dvorah Kimhi
Independent Director1.33yrsUS$26.14kno data
Elon Shalev
Director33.25yrsUS$3.05kno data
Erez Alroy
Director1.33yrsUS$2.54k0.18% $103.6k
Yariv Alroy
Chairman of the Board1.33yrsUS$2.54kno data
Yehoshua Abramovich
Independent Director2.83yrsUS$34.02kno data
Amir Lerman
Director4.17yrsUS$27.76kno data


Average Tenure


Average Age

Experienced Board: SHLTN's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

SHL Telemedicine Ltd.'s company bio, employee growth, exchange listings and data sources

Key Information

  • Name: SHL Telemedicine Ltd.
  • Ticker: SHLTN
  • Exchange: SWX
  • Founded: 1987
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: CHF57.767m
  • Shares outstanding: 10.50m
  • Website: https://www.shl-telemedicine.com

Number of Employees


  • SHL Telemedicine Ltd.
  • Ashdar Building
  • 90 Yigal Alon Street
  • Tel Aviv
  • 67891
  • Israel


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SHLTNSWX (SIX Swiss Exchange)YesRegistered SharesCHCHFNov 2000
SZODB (Deutsche Boerse AG)YesRegistered SharesDEEURNov 2000
SMDC.FOTCPK (Pink Sheets LLC)YesRegistered SharesUSUSDNov 2000
SHLTNZBATS-CHIXE (BATS 'Chi-X Europe')YesRegistered SharesGBCHFNov 2000
0QMXLSE (London Stock Exchange)YesRegistered SharesGBCHFNov 2000


SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally. The company offers smartheart, a personal mobile 12-lead ECG device that enables the detection of heart attacks; CardioSen’C, a personal cellular-digital 12-lead ECG transmitter; Cardio’B, a portable device to transmit a 12-lead ECG; and Cardio Beeper 12/12, a hand-held ECG transmitter device for personal use that transmits a full ECG reading to the monitoring center. It also provides central communication module, a telecommunication device that transmits medical data to its telemedicine centers from various medical monitoring devices; TeleWeight, a trans-telephonic weight monitoring device for personal use; TelePress, a remote blood pressure monitoring device for personal use; TeleBreather, a remote electronic handheld device to test the working of lungs; and TelePulse Oximeter, an electronic handheld diagnostic device to measure the saturation level of oxygen in blood, as well as pulse rate. The company offers its telemedicine services and devices to subscribers using telephonic and Internet communication technology. It serves patients, health insurance companies, hospitals, clinics, physicians, and other health care providers. The company was founded in 1987 and is headquartered in Tel Aviv, Israel. 

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/07 23:39
End of Day Share Price2020/04/07 00:00
Annual Earnings2018/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.